Retifanlimab

瑞弗利单抗

Report date: 2026/03/19 20:00:18

Base Information

Drug NameRetifanlimab
Drug Alias NameRetifanlimab-dlwrZYNYZZynyzINCMGA-0012INCMGA-00012 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[38] 
Global Approved IndicationsAnus NeoplasmsCarcinoma, Merkel Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/03/22
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSagard Healthcare PartnersInstitut BergoniéIncyte Corp +[9] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[33] 
Inactive IndicationsGastrointestinal NeoplasmsCarcinoma, EndometrioidMalignant Carcinoid Syndrome +[5] 

Other Information

ATC CodeL01FF10
Related LinksDrugBankKEGG